Y-Intercept (HK)’s Vertex Pharmaceuticals VRTX Stock Holding History

Y-Intercept (HK)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-8,281	Closed	-$4.11M	–	2132
2026 Q2	$4.11M	Sell	8,281 -27,548	-77%	-$12.2M	0.08%	347
2026 Q1	$16M	Buy	+35,829	New	+$16.7M	0.3%	41
2025 Q4	–	Sell	-27,770	Closed	-$10.9M	–	2020
2025 Q3	$10.9M	Buy	+27,770	New	+$11.6M	0.26%	59
2025 Q1	–	Sell	-5,385	Closed	-$2.17M	–	1641
2024 Q4	$2.17M	Buy	+5,385	New	+$2.5M	0.14%	187
2024 Q3	–	Sell	-4,683	Closed	-$2.2M	–	1849
2024 Q2	$2.2M	Buy	+4,683	New	+$2.03M	0.12%	224
2023 Q1	–	Sell	-9,719	Closed	-$2.81M	–	1570
2022 Q4	$2.81M	Buy	+9,719	New	+$2.96M	0.41%	22
2022 Q1	–	Sell	-7,996	Closed	-$1.76M	–	981
2021 Q4	$1.76M	Buy	+7,996	New	+$1.55M	0.42%	45
2021 Q2	–	Sell	-2,579	Closed	-$549K	–	932
2021 Q1	$549K	Buy	+2,579	New	+$566K	0.15%	231

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Y-Intercept (HK)'s VRTX Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 8,281 shares — an estimated $4.11M sold.

Y-Intercept (HK) first reported a position in VRTX in Q1 2021 and held it in 8 quarters. The position peaked at $16M in Q1 2026. 440 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Y-Intercept (HK) reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 8,281 Vertex Pharmaceuticals shares in Q3 2026, an estimated $4.11M.
Y-Intercept (HK) first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Y-Intercept (HK)'s Vertex Pharmaceuticals position peaked at $16M in Q1 2026.
440 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.